RG
Redmile Group Portfolio holdings
AUM
$940M
1-Year Return
75.78%
This Quarter Return
-5.25%
1 Year Return
+75.78%
3 Year Return
+543.67%
5 Year Return
+585.96%
10 Year Return
+6,653.82%
AUM
$7.1B
AUM Growth
-$1.16B
(-14%)
Cap. Flow
-$264M
Cap. Flow
% of AUM
-3.72%
Top 10 Holdings %
Top 10 Hldgs %
41.94%
Holding
104
New
17
Increased
24
Reduced
34
Closed
18
Top Buys
| 1 |
Jazz Pharmaceuticals
JAZZ
|
$136M |
| 2 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$130M |
| 3 |
Medtronic
MDT
|
$116M |
| 4 |
LivaNova
LIVN
|
$82.6M |
| 5 |
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
|
$80M |
Top Sells
| 1 |
AbbVie
ABBV
|
$149M |
| 2 |
Gilead Sciences
GILD
|
$133M |
| 3 |
ONEM
1Life Healthcare, Inc. Common Stock
ONEM
|
$107M |
| 4 |
Beam Therapeutics
BEAM
|
$99.7M |
| 5 |
Sanofi
SNY
|
$96.4M |
Sector Composition
| 1 | Healthcare | 95.05% |
| 2 | Financials | 0.83% |
| 3 | Consumer Staples | 0.3% |
| 4 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
GNMK
26
DELISTED
GenMark Diagnostics, Inc
GNMK
| $85.8M | 1.21% |
3,589,342
-948,058
| -21% | -$22.7M |
|
|
27
LivaNova
LIVN
$3.17B
| $82.6M | 1.16% |
+1,119,830
| New | +$82.6M |
|
28
Repare Therapeutics
RPTX
$72.6M
| $81.8M | 1.15% |
2,665,496
+17,800
| +0.7% | +$546K |
|
|
NGM
29
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $80M | 1.13% |
+2,751,815
| New | +$80M |
|
30
DexCom
DXCM
$31.6B
| $79.9M | 1.13% |
+889,832
| New | +$79.9M |
|
31
Regenxbio
RGNX
$490M
| $79.8M | 1.12% |
2,340,313
+216,821
| +10% | +$7.4M |
|
|
TCRR
32
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $79.7M | 1.12% |
3,610,788
+777,900
| +27% | +$17.2M |
|
|
IMGN
33
DELISTED
Immunogen Inc
IMGN
| $78.5M | 1.11% |
9,688,066
-840,113
| -8% | -$6.8M |
|
|
EPZM
34
DELISTED
Epizyme, Inc
EPZM
| $76.9M | 1.08% |
8,824,366
-625,939
| -7% | -$5.45M |
|
35
Akero Therapeutics
AKRO
$3.58B
| $72.9M | 1.03% |
2,513,746
+191,189
| +8% | +$5.55M |
|
36
ALX Oncology
ALXO
$65.3M
| $72.2M | 1.02% |
978,600
+18,200
| +2% | +$1.34M |
|
|
NVRO
37
DELISTED
NEVRO CORP.
NVRO
| $72.1M | 1.02% |
516,795
+72,886
| +16% | +$10.2M |
|
38
Atea Pharmaceuticals
AVIR
$267M
| $71.5M | 1.01% |
1,158,082
-1,073,628
| -48% | -$66.3M |
|
39
Celldex Therapeutics
CLDX
$1.52B
| $69.8M | 0.98% |
3,387,788
+676,172
| +25% | +$13.9M |
|
40
Cigna
CI
$81.5B
| $67.7M | 0.95% |
280,057
-103,036
| -27% | -$24.9M |
|
41
SelectQuote
SLQT
$358M
| $59.2M | 0.83% |
2,005,054
+160,335
| +9% | +$4.73M |
|
42
Neurogene
NGNE
$285M
| $50.7M | 0.71% |
205,878
-715
| -0.3% | -$176K |
|
43
Charles River Laboratories
CRL
$8.07B
| $48.3M | 0.68% |
+166,679
| New | +$48.3M |
|
44
Nuvation Bio
NUVB
$1.33B
| $47.5M | 0.67% |
+4,541,009
| New | +$47.5M |
|
45
Elevance Health
ELV
$70.6B
| $46.8M | 0.66% |
130,405
-113,927
| -47% | -$40.9M |
|
46
Prothena Corp
PRTA
$460M
| $46.7M | 0.66% |
+1,857,072
| New | +$46.7M |
|
47
ICU Medical
ICUI
$3.24B
| $46.1M | 0.65% |
224,154
-17,300
| -7% | -$3.55M |
|
48
Biogen
BIIB
$20.6B
| $45.6M | 0.64% |
162,847
-53,400
| -25% | -$14.9M |
|
|
KLRS
49
Kalaris Therapeutics, Inc. Common Stock
KLRS
$86.4M
| $45.5M | 0.64% |
84,504
-16,609
| -16% | -$8.94M |
|
50
Genmab
GMAB
$16.9B
| $43.7M | 0.62% |
+1,332,212
| New | +$43.7M |
|